Table 1.
Characteristics of patients at the time of osteoporotic screening.
| Characteristic | ZA group (n = 26) | Control (n = 12) | P-value |
|---|---|---|---|
| Age, yr | 80.5 ± 9.1 | 76.1 ± 6.7 | <0.05 |
| Body mass index, kg/m2 | 23.8 ± 3.5 | 23.4 ± 3.9 | NS |
| PSA level during intervention, ng/mL | 0.005 ± 0.21 | 0.004 ± 0.21 | NS |
| Duration of ADT, mo | 40.0 ± 5.5 | 40.5 ± 5.5 | NS |
| Serum corrected Calcium, mg/dL | 9.5 ± 0.20 | 9.4 ± 0.25 | NS |
| FRAX 10-year MOF rate, % | 16.0 ± 6.9 | 10.5 ± 6.5 | <0.05 |
| FRAX 10-year HF rate, % | 10.0 ± 5.7 | 4.5 ± 4.0 | <0.05 |
| Serum creatinine, mg/mL | 0.92 ± 0.3 | 0.94 ± 0.3 | NS |
| Lumbar BMD, g/cm2 | 1.034 ± 0.197 | 1.2385 ± 0.192 | <0.05 |
| Hip BMD, g/cm2 | 0.732 ± 0.245 | 0.942 ± 0.206 | <0.05 |
Values are presented as mean ± standard deviation.
ZA, zoledronic acid 5 mg intravenously; PSA, prostate-specific antigen; ADT, androgen deprivation therapy; FRAX, fracture risk assessment tool; MOF, major osteoporotic fracture; HF, hip fracture; BMD, bone mineral density; NS, not significant.